Burkhard Brandt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8943531/publications.pdf

Version: 2024-02-01

94 papers 7,985

40 h-index 87 g-index

97 all docs 97
docs citations

97 times ranked 12362 citing authors

#	Article	IF	CITATIONS
1	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. Cancers, 2021, 13, 2613.	1.7	10
2	Longitudinal Analysis of Circulating Tumor Cells in Colorectal Cancer Patients by a Cytological and Molecular Approach: Feasibility and Clinical Application. Frontiers in Oncology, 2021, 11, 646885.	1.3	10
3	Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression. Journal of Personalized Medicine, 2021, 11, 1088.	1.1	3
4	EGFR as a stable marker of prostate cancer dissemination to bones. British Journal of Cancer, 2020, 123, 1767-1774.	2.9	27
5	Low Numbers of Vascular Vessels Correlate to Progression in Hormone-NaÃ-ve Prostate Carcinomas Undergoing Radical Prostatectomy. Cancers, 2019, 11, 1356.	1.7	7
6	ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer. Translational Research, 2019, 203, 49-56.	2.2	13
7	Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer. International Journal of Cancer, 2019, 144, 607-614.	2.3	11
8	BRCAness in prostate cancer. Oncotarget, 2019, 10, 2421-2422.	0.8	6
9	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget, 2017, 8, 106415-106428.	0.8	42
10	Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy. International Journal of Molecular Sciences, 2015, 16, 3856-3869.	1.8	15
11	EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer. Targeted Oncology, 2014, 9, 43-52.	1.7	5
12	AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. Cellular Signalling, 2014, 26, 1021-1029.	1.7	37
13	Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases. American Journal of Pathology, 2013, 183, 83-95.	1.9	63
14	Genome-Wide Investigation of Multifocal and Unifocal Prostate Cancer — Are They Genetically Different?. International Journal of Molecular Sciences, 2013, 14, 11816-11829.	1.8	18
15	Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. European Journal of Cancer, 2012, 48, 2066-2074.	1.3	7
16	15â€Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial–mesenchymal transition, and promotes cell migration in cultured breast cancer cells. Journal of Pathology, 2012, 226, 674-686.	2.1	32
17	Site-specific chromatin immunoprecipitation: a selective method to individually analyze neighboring transcription factor binding sites in vivo. BMC Research Notes, 2012, 5, 109.	0.6	10
18	Pro-Inflammatory wnt5a and Anti-Inflammatory sFRP5 Are Differentially Regulated by Nutritional Factors in Obese Human Subjects. PLoS ONE, 2012, 7, e32437.	1.1	108

#	Article	IF	Citations
19	Quantitative High-Resolution Genomic Analysis of Single Cancer Cells. PLoS ONE, 2011, 6, e26362.	1.1	30
20	Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cellular Signalling, 2011, 23, 1952-1960.	1.7	76
21	Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Research and Treatment, 2011, 125, 729-738.	1.1	33
22	Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells. Clinical and Experimental Metastasis, 2011, 28, 75-90.	1.7	63
23	Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptorâ€positive, invasive breast cancer. Journal of Pathology, 2011, 224, 517-528.	2.1	28
24	Cellular and Tumor Radiosensitivity is Correlated to Epidermal Growth Factor Receptor Protein Expression Level in Tumors Without EGFR Amplification. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1181-1188.	0.4	38
25	Discovery of a Novel Unfolded Protein Response Phenotype of Cancer Stem/Progenitor Cells from the Bone Marrow of Breast Cancer Patients. Journal of Proteome Research, 2010, 9, 3158-3168.	1.8	89
26	Selective regain of egfr gene copies in CD44+/CD24-/lowbreast cancer cellular model MDA-MB-468. BMC Cancer, 2010, 10, 78.	1.1	19
27	<i>BRCA1</i> Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood. Clinical Cancer Research, 2010, 16, 3340-3348.	3.2	73
28	Inositol 1,4,5-Trisphosphate 3-Kinase-A Is a New Cell Motility-promoting Protein That Increases the Metastatic Potential of Tumor Cells by Two Functional Activities. Journal of Biological Chemistry, 2010, 285, 5541-5554.	1.6	40
29	TOB1 Is Regulated by EGF-Dependent HER2 and EGFR Signaling, Is Highly Phosphorylated, and Indicates Poor Prognosis in Node-Negative Breast Cancer. Cancer Research, 2009, 69, 5049-5056.	0.4	37
30	Two-Dimensional Differential Gel Electrophoresis of a Cell Line Derived from a Breast Cancer Micrometastasis Revealed a Stem/Progenitor Cell Protein Profile. Journal of Proteome Research, 2009, 8, 2004-2014.	1.8	48
31	Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (<i>EGFR</i>) in high grade central osteosarcomas. Genes Chromosomes and Cancer, 2008, 47, 657-664.	1.5	26
32	Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. British Journal of Cancer, 2008, 99, 774-780.	2.9	47
33	Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer, 2008, 8, 329-340.	12.8	1,037
34	Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer, 2008, 8, 339.	1.1	47
35	Molecular targeted therapies for breast cancer treatment. Breast Cancer Research, 2008, 10, 211.	2.2	63
36	Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells. Current Cancer Drug Targets, 2008, 8, 431-445.	0.8	21

#	Article	IF	CITATIONS
37	Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome. Clinical Cancer Research, 2007, 13, 2998-3005.	3.2	38
38	Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncology Reports, 2007, 17, 355-9.	1.2	44
39	Cytokeratin alteration in oral leukoplakia and oral squamous cell carcinoma. Oncology Reports, 2007, 18, 639-43.	1.2	41
40	(CA)n Microsatellite polymorphism of ERBB-1 in breast cancer. European Journal of Cancer, 2006, 42, 1698-1701.	1.3	2
41	The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy. Analytical Cellular Pathology, 2006, 28, 223-232.	0.7	21
42	Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Laboratory Investigation, 2006, 86, 54-61.	1.7	73
43	Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 42-52.	3.3	30
44	Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer, 2006, 6, 10.	1.1	99
45	Improvements in the Analysis Strategy Make Single Nucleotide Polymorphism Analysis a Powerful Tool in the Detection and Characterization of Amplified Chromosomal Regions in Human Tumors. Pathobiology, 2006, 73, 18-25.	1.9	1
46	HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 1715-1720.	3.2	249
47	Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response. Clinical Cancer Research, 2006, 12, 7252-7260.	3.2	101
48	Asynchronous Growth of Prostate Cancer Is Reflected by Circulating Tumor Cells Delivered from Distinct, Even Small Foci, Harboring Loss of Heterozygosity of the PTEN Gene. Cancer Research, 2006, 66, 8959-8965.	0.4	65
49	3D-extravasation model – selection of highly motile and metastatic cancer cells. Seminars in Cancer Biology, 2005, 15, 387-395.	4.3	19
50	In vitro and in vivo imaging of cell migration: Two interdepending methods to unravel metastasis formation. Seminars in Cancer Biology, 2005, 15, 396-404.	4.3	33
51	HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer, 2005, 5, 84.	1.1	115
52	Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials, 2005, 26, 5251-5258.	5.7	157
53	The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?. Journal of Pathology, 2005, 206, 451-457.	2.1	189
54	Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Endocrine-Related Cancer, 2005, 12, 823-837.	1.6	29

#	Article	IF	CITATIONS
55	Catenin expression in $T1/2$ carcinomas of the floor of the mouth. International Journal of Oral and Maxillofacial Surgery, 2005, 34, 907-911.	0.7	12
56	Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. Biochemical and Biophysical Research Communications, 2005, 329, 318-323.	1.0	8
57	Modification of Breast Cancer Risk in Young Women by a Polymorphic Sequence in the egfr Gene. Cancer Research, 2004, 64, 7-12.	0.4	73
58	Antitumour effects of PLC- $\hat{1}^3$ 1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. British Journal of Cancer, 2004, 90, 230-235.	2.9	39
59	Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. British Journal of Cancer, 2004, 90, 1422-1428.	2.9	32
60	Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Laboratory Investigation, 2004, 84, 582-587.	1.7	71
61	Allelic length of a CA dinucleotide repeat in theegfr gene correlates with the frequency of amplifications of this sequence—first results of an inter-ethnic breast cancer study. Journal of Pathology, 2004, 203, 545-550.	2.1	94
62	Evaluation of an in situ setting injectable calcium phosphate as a new carrier material for gentamicin in the treatment of chronic osteomyelitis: Studies in vitro and in vivo. Biomaterials, 2004, 25, 4287-4295.	5.7	87
63	Semi-Quantitative Immunochromatographic Test for Prostate Specific Antigen in Whole Blood: Tossing the Coin to Predict Prostate Cancer?. European Urology, 2003, 43, 478-484.	0.9	31
64	MALAT-1, a novel noncoding RNA, and thymosin \hat{l}^24 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene, 2003, 22, 8031-8041.	2.6	1,986
65	A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer. Clinical Chemistry and Laboratory Medicine, 2003, 41, 90-4.	1.4	8
66	Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Research, 2003, 63, 1172-8.	0.4	61
67	Cancer Cell Motilityâ€"On the Road from c-erbB-2 Receptor Steered Signaling to Actin Reorganization. Experimental Cell Research, 2002, 272, 93-108.	1.2	97
68	Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer, 2002, 36, 265-270.	0.9	79
69	Combining Free and Total Prostate Specific Antigen Assays from Different Manufacturers: The Pitfalls. European Urology, 2002, 42, 577-582.	0.9	12
70	Trimodality treatment in Stage III nonsmall cell lung carcinoma. Cancer, 2002, 94, 2055-2062.	2.0	51
71	Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept. Laboratory Investigation, 2002, 82, 737-745.	1.7	252
72	Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis. Laboratory Investigation, 2002, 82, 1525-1533.	1.7	221

#	Article	IF	Citations
73	Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. Cancer Research, 2002, 62, 1020-4.	0.4	19
74	Do Modifications of Nonequimolar Assays for Total Prostate-specific Antigen Improve Detection of Prostate Cancer?. Clinical Chemistry, 2001, 47, 1472-1475.	1.5	26
75	The clinical impact of different assays for prostate specific antigen. BJU International, 2001, 86, 590-597.	1.3	40
76	Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. European Respiratory Journal, 2000, 16, 991-996.	3.1	48
77	Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit thein vitro growth of human head and neck cancer cells and cause rapid tumor regressionin vivo., 2000, 86, 269-275.		92
78	Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology, 2000, 37, 411-419.	1.6	63
79	Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo., 2000, 86, 269.		1
80	Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1. Journal of Biological Chemistry, 1999, 274, 13176-13180.	1.6	338
81	Density Gradient Centrifugation of Colonic Fluid After Segmental Lavage: A Method of Purification of Exfoliative Epithelial Colonic Cells for Cytological Interpretation and Image Cytometry in Patients With Long-Standing Ulcerative Colitis. American Journal of Gastroenterology, 1999, 94, 404-409.	0.2	6
82	Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients., 1998, 76, 824-828.		70
83	Differential Expression of Alternatively Spliced c-erbB-2 mRNA in Primary Tumors, Lymph Node Metastases, and Bone Marrow Micrometastases from Breast Cancer Patients. Biochemical and Biophysical Research Communications, 1998, 247, 319-323.	1.0	24
84	Selection of Potentially Metastatic Subpopulations Expressing c-erbB-2 from Breast Cancer Tissue by Use of an Extravasation Model. American Journal of Pathology, 1998, 153, 1797-1806.	1.9	58
85	Competitive-Differential Polymerase Chain Reaction for Gene Dosage Estimation oferbB-1 (egfr),erbB-2, anderbB-3 Oncogenes. DNA and Cell Biology, 1997, 16, 443-448.	0.9	20
86	Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clinical Chemistry, 1997, 43, 1588-1594.	1.5	33
87	Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology, 1996, 48, 10-15.	0.5	81
88	The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. American Journal of Surgery, 1996, 172, 681-683.	0.9	39
89	Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate, 1996, 29, 3-16.	1.2	70
90	Detection of the metastatic potential of blood-borne and immunomagnetically enriched epithelial cells by quantitative erbB-2 RT-PCR. Clinical and Experimental Metastasis, 1996, 14, 399-408.	1.7	8

#	Article	IF	CITATIONS
91	Immunophenotyping of Lymphocytes in Bronchoalveolar Lavage Fluid. Chest, 1995, 108, 464-469.	0.4	20
92	Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene, 1995, 159, 29-34.	1.0	32
93	Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: Double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene, 1995, 159, 35-42.	1.0	42
94	An immunological enrichment method for epithelial cells from peripheral blood. Journal of Immunological Methods, 1995, 183, 251-265.	0.6	83